Eczematous Eruption During Bimekizumab Treatment in a Psoriatic Patient Previously Treated with Secukinumab
Overview
Overview
Journal
Skin Health Dis
Publisher
Oxford University Press
Specialty
Dermatology
Date
2024 Oct 2
PMID
39355729
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
Several eczematous eruptions have been described during treatment with anti-IL17A and anti-IL17 receptor drugs. In our case, however, the patient had been treated for 2 years with an IL-17A inhibitor without ever developing eczematous reactions, which occurred, however, shortly after starting therapy with bimekizumab, an IL-17A, F and A/F inhibitor.
References
1.
Al-Janabi A, Foulkes A, Mason K, Smith C, Griffiths C, Warren R
. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2020; 34(7):1440-1448.
DOI: 10.1111/jdv.16246.
View
2.
Megna M, Caiazzo G, Parisi M, Ruggiero A, Capasso G, Mascolo M
. Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role?. Clin Exp Dermatol. 2021; 47(5):918-925.
DOI: 10.1111/ced.15052.
View
3.
Caldarola G, Pirro F, Di Stefani A, Talamonti M, Galluzzo M, DAdamio S
. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. Expert Opin Biol Ther. 2020; 20(6):665-672.
DOI: 10.1080/14712598.2020.1727439.
View
4.
Lauffer F, Jargosch M, Baghin V, Krause L, Kempf W, Absmaier-Kijak M
. IL-17C amplifies epithelial inflammation in human psoriasis and atopic eczema. J Eur Acad Dermatol Venereol. 2019; 34(4):800-809.
DOI: 10.1111/jdv.16126.
View
5.
Chang S, Reynolds J, Pappu B, Chen G, Martinez G, Dong C
. Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity. 2011; 35(4):611-21.
PMC: 5800502.
DOI: 10.1016/j.immuni.2011.09.010.
View